The weekly litigation news digest is live. Subscribe now

IP Verse

Eliglustat (Genz 112638) As Inhibitor Of Glucosylceramide Synthase For Use In A Method Of Treating Fabry'S Or Gaucher'S Disease, The Method Comprising Adjusting The Individual Therapeutical Dose To The P-450 Metabolism Of The Patient - EP3133070

The patent EP3133070 was granted to Genzyme on Aug 14, 2019. The application was filed on Nov 24, 2010 under application number EP16175117A. The patent is currently recorded with a legal status of "Revoked".

EP3133070

GENZYME
Application Number
EP16175117A
Filing Date
Nov 24, 2010
Status
Revoked
May 19, 2025
Publication Date
Aug 14, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
ACCORD HEALTHCAREMay 14, 2020BRAND MURRAY FULLERADMISSIBLE
HETERO LABSMay 14, 2020ZBM PATENTS APSADMISSIBLE
TEVA PHARMACEUTICALSMay 13, 2020D YOUNGADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS5916911
DESCRIPTIONUS5945442
DESCRIPTIONUS5952370
DESCRIPTIONUS6030995
DESCRIPTIONUS6051598
DESCRIPTIONUS7253185
OPPOSITIONWO03008399
OPPOSITIONWO2008150486
SEARCHWO2008150486

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents